The facilities are located in the center of
Philadelphia's thriving life
sciences corridor
PHILADELPHIA, May 16, 2022
/PRNewswire/ -- Spirovant Sciences, a gene therapy company
developing treatments for respiratory diseases, including cystic
fibrosis (CF), announced today the launch of its new
state-of-the-art research laboratory and corporate headquarters in
Philadelphia. The new research
facilities will allow the company to accelerate development of its
lead program targeting CF, support the vector manufacturing
process, and build capabilities to grow its platform and pipeline
into therapeutic opportunities.
"Our growth and maturity as a leading gene therapy company have
propelled us to expand into the new research facilities where we
will redouble our efforts to develop promising treatments and cures
for patients with respiratory diseases such as CF," said Joan
Lau, CEO of Spirovant Sciences. "Our diverse team of talented
researchers and drug development professionals is committed to
advancing promising drug candidates as a cornerstone of biotech
innovation in Philadelphia."
"With a first investment and ongoing commercialization support
from the Science Center, and the expansion here at uCity Square, we
celebrate the success and continued growth of Spirovant Sciences,"
said Tiffany Wilson, President &
CEO of the University City Science Center. "Spirovant Sciences is a
true success story for the Science Center, uCity Square, and
Philadelphia's vibrant life
sciences ecosystem."
The new laboratory space is in the uCity Square district,
located in the heart of the University City neighborhood t,
surrounded by leading universities, academic medical centers and
numerous outstanding technology, life sciences, and healthcare
organizations. The laboratory allows the Spirovant scientists to
conduct innovative R&D in respiratory biology and within
process and analytical sciences.
"As a company that started here, stayed here and has grown here,
Spirovant is a leading example of the success of Philadelphia's booming cell and gene therapy
ecosystem, and we are excited they have chosen to continue growing
their team and their therapies here in uCity Square," said
John Grady Senior Vice President and
Northeast Region Executive for Wexford Science and Technology,
developer of the uCity Square knowledge
community.
"I am thrilled about Spirovant's move into the new laboratory
space and corporate headquarters," said Myrtle Potter, CEO of Sumitovant, Spirovant's
parent company. "The greater Philadelphia region is well known for its
dynamic business environment in the field of gene and cell therapy,
and we expect the entrepreneurial spirit of the region to reflect
positively on Spirovant's ambitions and talent."
About Spirovant Sciences
Spirovant is a gene therapy company focused on changing the
course of cystic fibrosis and other respiratory diseases. The
company's current investigational gene therapy technologies are
designed to overcome the historical barriers that have prevented
effective genetic treatments for cystic fibrosis. Spirovant's lead
programs are in development for cystic fibrosis. Spirovant, a
wholly owned subsidiary of Sumitovant Biopharma, is located
in Philadelphia, PA. For more information, please visit
our website at spirovant.com.
About Sumitovant
Biopharma
Sumitovant is a global biopharmaceutical company leveraging
data-driven insights to rapidly accelerate development of new
potential therapies. Through our unique portfolio of
companies—wholly owned Urovant, Enzyvant, Spirovant, Altavant, plus
majority-owned Myovant (NYSE: MYOV)—and use of embedded
computational technology platforms to generate business and
scientific insights, Sumitovant has supported the development of
FDA-approved products and advanced a promising pipeline of
early-through late-stage investigational assets for other serious
conditions. Sumitovant is a wholly owned subsidiary of Sumitomo
Pharma. For more information, please visit our website at
sumitovant.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spirovant-launches-state-of-the-art-laboratory-and-headquarters-301547540.html
SOURCE Spirovant Sciences